EN

Summary of the EU4Health – work programme for 2025

This is the summary of the Annex to the Commission Implementing Decision on the EU4Health programme for 2025[1], which sets out priorities and actions, including the allocation of resources, for the implementation in 2025 of the EU4Health Programme as provided for under Regulation (EU) 2021/522 of the European Parliament and of the Council[2] ('the EU4Health Regulation').

The overall budget for 2025 amounts to **EUR 571 347 315**[3], of which EUR 195 464 733 will be grants, EUR 281 702 582 will be procurement, EUR 2 730 000 will be other expenditures (all under direct management), and EUR 91 450 000 will be under indirect management.

The EU4Health programme represents an unprecedented level of financial commitment for the EU in the area of health in comparison with the previous health programmes.

The general objectives and specific objectives of the EU4Health programme are laid down in Articles 3 and 4 of Regulation (EU) 2021/522, and are implemented on the basis of the **strands** and **areas of actions** set out in the table below.

Table: Strands & areas of action

STRANDS AND AREAS OF ACTION	2025 budget (in EUR)
1. CRISIS PREPAREDNESS (CP)	**380 995 165**
HEALTH EMERGENCY PREPAREDNESS AND RESPONSE AUTHORITY (HERA)	357 645 165
ONE HEALTH SURVEILLANCE	15 000 000
IMPLEMENTATION OF THE REGULATION ON SERIOUS CROSS BORDER THREATS TO HEALTH	6 500 000
BIOLOGICAL AND CHEMICAL HAZARDS	1 000 000
MOSQUITO VECTOR MONITORING	600 000
STUDY ON THE IMPLEMENTATION OF THE EU ONE HEALTH ACTION PLAN AGAINST AMR	250 000

1 https://ec.europa.eu/health/funding/programme_en .

2 Regulation (EU) 2021/522 of the European Parliament and of the Council of 24 March 2021 establishing a Programme for the Union's action in the field of health ('EU4Health Programme') for the period 2021-2027 and repealing Regulation (EU) No 282/2014 (OJ L 107, 26.3.2021, p. 1).

3 The amount includes contributions from associated EEA EFTA countries to the EU4Health programme as well as contributions from candidate countries and Western Balkan potential candidates.

2. HEALTH PROMOTION AND DISEASE PREVENTION (DP)	**7 605 000**
TOBACCO CONTROL POLICY	1 660 000
EUROPEAN REFERENCE NETWORKS AND ORPHANET	3 980 000
HEALTH POLICY PLATFORM AND SCIENTIFIC COMMITTEES	1 265 000
EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES PARTNERSHIP	700 000
3. CANCER, CARDIOVASCULAR AND OTHER NON-COMMUNICABLE DISEASES (CR/CV&NCDS)	**60 580 000**
CANCER SCREENING PROGRAMMES (GASTRIC, LUNG AND PROSTATE)	17 880 000
EUROPE'S BEATING CANCER PLAN ANNUAL EVENT AND ADMINISTRATIVE SUPPORT TO THE PLAN'S GOVERNANCE	200 000
SUPPORTING IMPLEMENTATION OF THE STRATEGIC AGENDA FOR MEDICAL IONISING RADIATION APPLICATIONS (SAMIRA)	11 500 000
A EUROPEAN FLAGSHIP INITIATIVE LEVERAGING AI AND HEALTH DATA FOR CARDIOVASCULAR HEALTH AND RELATED NON-COMMUNICABLE DISEASES: ADVANCING RISK PREDICTION, PREVENTION, TREATMENTS, PERSONALISED CARE AND REHABILITATION	20 000 000
HEALTHY LONGEVITY AND LIFELONG PREVENTION: CARDIOVASCULAR DISEASES	11 000 000
4. HEALTH SYSTEMS AND HEALTHCARE WORKFORCE (HS)	**71 415 000**
STATE OF HEALTH IN THE EU	4 150 000
IMPLEMENTATION OF THE HEALTH TECHNOLOGY ASSESSMENT REGULATION	11 300 000
IMPLEMENTATION OF THE PHARMACEUTICAL LEGISLATION AND STRATEGY	16 800 000
IMPLEMENTATION OF THE CLINICAL TRIALS REGULATION	6 500 000
IMPLEMENTATION OF THE LEGISLATION ON BLOOD, TISSUES AND CELLS AND ORGANS	10 000 000
IMPLEMENTATION OF REGULATIONS ON MEDICAL DEVICES AND IN VITRO MEDICAL DEVICES[4]	18 690 000
CROSS-BORDER HEALTHCARE	75 000
HEALTH UNION FELLOWSHIP PROGRAMME	1 400 000
EU GLOBAL HEALTH STRATEGY	2 500 000

[4] Including the Joint assessment of Notified Bodies.

5. DIGITAL (DI)	**39 686 810**
ENHANCING HEALTH DATA ACCESS BODIES	14 400 000
HEALTH DATA FOR BIOTECH INNOVATION: LEVERAGING THE EUROPEAN HEALTH DATA SPACE	14 386 810
ADMINISTRATIVE AND LOGISTICAL SUPPORT TO THE EHDS AND DIGITAL ACTIONS	1 000 000
DEVELOPMENT, DEPLOYMENT AND OPERATIONS OF THE CENTRAL SERVICES OF THE INFRASTRUCTURE ON PRIMARY USES OF HEALTH DATA, MYHEALTH@EU	2 500 000
DEVELOPMENT, DEPLOYMENT AND OPERATIONS OF THE CENTRAL SERVICES OF THE INFRASTRUCTURE ON SECONDARY USES OF HEALTH DATA, HEALTHDATA@EU	1 000 000
ACTIONS FOR EU-LEVEL INFRASTRUCTURES AND SERVICES IN THE EHDS	4 000 000
COMPLIANCE CHECKS FOR MYHEALTH@EU	2 400 000
6. OTHER ACTIONS	**11 065 340**
ORGANISATION OF CONFERENCES AND EVENTS	600 000
COMMUNICATION ACTIVITIES	4 838 340
IT RECURRENT ACTIVITIES	4 000 000
TRANSLATION SERVICES	210 000
EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HADEA) EXPERT EVALUATORS AND MONITORS	772 000
ENLARGEMENT CONFORMITY STUDY	425 000
INTERNATIONAL MEDICAL DEVICE REGULATORY FORUM	200 000
REIMBURSEMENT OF EXPERTS PARTICIPATING IN COMMISSION CONTROLS AND AUDITS IN THE PHARMACEUTICAL FIELD	20 000

The **actions proposed for funding** are set out in the bullet points below and cover five main areas: (i) action grants; (ii) procurement; (iii) IT support; (iv) other actions under direct management; and (v) actions under indirect management.

Action grants

Calls for proposals to support:

a) the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats – HERA;
b) the development of new diagnostic tests for vector-borne diseases – HERA;
c) piloting and implementing cancer screening programmes for gastric cancer;
d) piloting and implementing cancer screening programmes for lung cancer;
e) piloting and implementing cancer screening programmes for prostate cancer;
f) a European flagship initiative leveraging AI and health data for cardiovascular health and related non-communicable diseases: Advancing Risk Prediction, Prevention, Treatments, Personalised Care and Rehabilitation;
g) Lifelong prevention for a healthy life with focus on cardiovascular diseases;

h) developing a medicine pricing, reimbursement and access tracker through the EURIPID database;
i) programme on orphan medical devices, in particular targeting paediatric patients;
j) health data for biotech innovation leveraging the European Health Data Space;
k) contribution to the organisation of conferences and events.

Grants for actions co-financed with Member States' authorities / joint actions:

a) scaling up of national systems for vector threat detection and control capacities – HERA;
b) implementation of HERA's training and exercise programme for management of medical countermeasures – HERA;
c) supporting the implementation of the strategic agenda for medical ionising radiation applications (SAMIRA);
d) lifelong prevention for a healthy life, including through screening, with focus on cardiovascular diseases;
e) supporting the implementation of a common standard for medical product identification and AI capabilities across Member States;
f) quality of medicines and implementation of the pharmaceutical legislation and the Pharmaceutical Strategy for Europe;
g) providing regulatory or scientific advice to small and micro-enterprises to support the development and carrying out of the conformity assessment of devices, particularly innovative devices, and to facilitate Union-level coordination on medical device safety issues;
h) implementation of Clinical Trials Regulation and improving the clinical trials landscape with Member States and EEA countries, including through pilots and training;
i) supporting non-commercial sponsors active in clinical trials;
j) maximising the impact of the EU Global Health Strategy.

Grants for actions co-financed with Member States' authorities / direct grants:

a) enhancing whole genome sequencing (WGS) and/or reverse transcription polymerase chain reaction (RT-PCR) national infrastructures and capacities to respond to the COVID-19 pandemic and future health threats – HERA;
b) setting up a coordinated surveillance system under the One Health approach for cross-border pathogens that threaten the EU;
c) supporting the maintenance of the European Medical Device Nomenclature;
d) enhancing health data access bodies with focus on the secondary use of health data.

Other direct grants to support:

a) the Africa Centres for Disease Control and Prevention (Africa CDC), the African Society for Laboratory Medicine (ASLM), and the Asia Pathogen Genomics Initiative (Asia PGI) to support wastewater surveillance for the early detection of health threats – HERA;
b) the functioning of designated EU reference laboratories in accordance with Regulation (EU) 2022/2371 on serious cross-border threats to health;
c) disease codification knowledge and information sharing with Orphanet;
d) EU reference laboratories for the Union contribution on in vitro diagnostic medical devices (under Regulation (EU) 2017/746).

Procurement under direct management:

a) ever-warm facilities (EU FAB) for vaccine production – HERA;
b) manufacturing investments and manufacturing capacity reservation contracts to strengthen the supply of medical countermeasures – HERA;
c) speeding up the development of, access to and/or uptake of medical countermeasures– HERA;
d) purchase, innovation and deployment of medical countermeasures in emergency situations –

HERA;

e) IT development for early warning, modelling, simulation and forecasting (ATHINA 2.0) – HERA;
f) global and EU wastewater sentinel system – HERA;
g) support to the Commission on gathering intelligence on priority threats and medical countermeasures – HERA;
h) training and exercise programme for management of medical countermeasures – HERA;
i) study on the implementation of the monitoring framework of the EU One Health Action Plans against AMR and Council Recommendation on stepping up EU actions to combat antimicrobial resistance taking a One Health approach;
j) tobacco control policy: operation of technical group on characterising flavours;
k) Union-level event on patients' rights in cross-border healthcare and the European Reference Networks;
l) amendment to the ERNs evaluation methodology;
m) Europe's Beating Cancer Plan annual event and administrative support to the plan's governance mechanism and stakeholder engagement;
n) support to the secretariat of the Member State coordination group on HTA - HTACG;
o) supporting the joint work of Member States in the field of HTA assessment;
p) implementation of the pharmaceutical legislations and data-driven policy for medical products;
q) preparation for the implementation of the reform of the Union pharmaceutical legislation;
r) study on the application of Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices;
s) supporting and facilitating the implementation of the substances of human origin ('SoHO') regulation, including dissemination and training of SoHO profressionals;
t) supporting joint work of Member States in the field of substances of SoHO;
u) strengthening national implementation of organ transplant practices, in particular through and in cooperation between national authorities and professional sector associations;
v) training and networking of SoHO competent authorities' staff for oversight;
w) yearly data collection on patient mobility, Directive (2011/24/EU) on the application of patients' rights in cross-border healthcare;
x) technical assistance to support the implementation of Medical Devices Regulation (EU) 2017/745 / In Vitro Devices Regulation (EU) 2017/746;
y) studies supporting better regulation activities in the field of medical devices and in vitro medical devices;
z) programme of continuous learning within a European Health Union professional network;
aa) administrative and logistical support to the European Health Data Space ('EHDS') and other actions in the area of digital health;
bb) compliance checks for MyHealth@EU;
cc) development, deployment and operations of the central services of the infrastructure on primary uses of health data (MyHEALTH@EU);
dd) development, deployment and operations of the central services of the infrastructure on secondary uses of health data (HEALTHDATA@EU);
ee) actions for EU-level infrastructures and services in the context of the EHDS;
ff) better regulation FWC.

IT support:

a) Tobacco control policy: operation of IT databases;
b) Health Policy Platform;
c) continuous development and maintenance of the HTA IT platform;

d) support to the European Medicinal Products database;
e) development of SoHO Digital Platform ('SoHO-X');
f) support to European database on medical devices ('EUDAMED').
g) data analytics, supporting services, network solutions and other IT recurrent;

Other:

Annual membership fees for international organisations and regulatory bodies and other expenditures.

a) Euromonitor online database;
b) European Observatory of Health Systems and Policies;
c) International Pharmaceutical Regulators Programme;
d) International Council for Harmonisation ('ICH') of Technical Requirements for Pharmaceuticals for Human Use;
e) participation of experts from Member States in ICH meetings;
f) methodologies for assessment of safety and performance or market surveillance of silicone-containing medical devices;
g) joint assessment of notified bodies and associated training for experts;
h) peer review between authorities responsible for notified bodies;
i) meetings of standing committees, ad hoc meetings, committees and other events;
j) support for the assessment of regulatory alignment with EU law in the context of enlargement;
k) scientific committees, functioning of experts' groups, meetings and technical assistance;
l) participation of EU delegates in International Medical Device Regulators Forum ('IMDRF') and Medical Device Single Audit Programme ('MDSAP'), and experts participating in Commission controls and audits in the pharmaceutical field, including in relation to GMP and/or GDP;
m) HaDEA expert evaluators and monitoring of certain projects;
n) communication activities;
o) translations.

Actions implemented under indirect management:

a) Kreditanstalt für Wiederaufbau - supporting the development of MCM against AMR to strengthen global preparedness and response (GARDP) – HERA;
b) European Investment Bank – blending under the thematic innovation financial product implemented by the European Investment Bank under the Invest EU Programme – HERA;
c) Agence Française de Développement - supporting the development of dengue medical countermeasures, anticipating growing needs in the Union due to climate change – HERA;
d) WHO – support to pandemic and epidemic intelligence – HERA;
e) UN Quadripartite (FAO, UNEP, WHO, or WHOAH) – support to the independent antimicrobial resistance evidence panel for global policy and response – HERA;
f) WHO – strengthening global antimicrobial resistance response – HERA;
g) European Investment Bank – supporting the G7 Surge financing initiative for MCMs and the accessibility and availability of MCMs through innovative funding mechanisms – HERA;
h) OECD – economic case for strengthening public health prevention preparedness and response to biological and chemical hazards;
i) European Centre for Disease Prevention and Control - prevention of the entry of the dengue, chikungunya and zika transmitting mosquitoes;
j) WHO – fostering healthy longevity and promoting lifelong prevention;
k) OECD – investing in health promotion and disease prevention across the lifespan;

l) OECD – State of Health in the EU - 6th cycle 'Health at a Glance Europe 2026', country health profiles 2027, synthesis report 2027;
m) WHO – State of Health in the EU - 6th cycle, preparation of country profiles 2027 and synthesis report 2027;
n) EMA – electronic product information for medicinal products.